Cancer treatment makes tumor vulnerable to immune system attack, research finds | The Jerusalem Post

This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.

Raccontata dajpost.com